StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
ANIXBullishIndustry Newsnews
High materiality7/10

Anixa to Present Ovarian Cancer CAR-T Data at ES MO Immuno-Oncology Congress 2026

Nov 4, 2026, 8:40 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive trial progression (no DLTs, higher-dose cohorts) and a high-profile ES MO presentation can re-rate growth potential; however, results are still early-phase and execution risk remains, limiting upside if readouts disappoint.

AI summary

What happened, with direct paths to the underlying reporting

Anixa Biosciences announced a Phase 1 CAR-T program for ovarian cancer is advancing at Moffitt Cancer Center, with the fifth cohort completed and a sixth cohort planned at a higher dose. Dr. Wenham will present at ES MO Immuno-Oncology Congress 2026 in London on December 14, 2026. Early safety looks favorable, with no dose-limiting toxicities and encouraging signs of disease stabilization and longer survivals, potentially acting as a near-term catalyst for ANIX.

  • ANIX to present ovarian cancer CAR-T data at ES MO 2026 in London.
  • Fifth cohort completed; dosing moves to 1x10^8 CAR+ cells/kg.
  • No dose-limiting toxicities observed; early signs of efficacy reported.
  • Trial dose escalation progressing; supportive safety signals and one-year survivals.
  • Collaboration with Moffitt Cancer Center under CER-T platform.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event